121 related articles for article (PubMed ID: 26401696)
21. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
[TBL] [Abstract][Full Text] [Related]
22. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.
Bullock R; Erkinjuntti T; Lilienfeld S;
Dement Geriatr Cogn Disord; 2004; 17(1-2):29-34. PubMed ID: 14560062
[TBL] [Abstract][Full Text] [Related]
23. The effects of galantamine treatment on caregiver time in Alzheimer's disease.
Sano M; Wilcock GK; van Baelen B; Kavanagh S
Int J Geriatr Psychiatry; 2003 Oct; 18(10):942-50. PubMed ID: 14533127
[TBL] [Abstract][Full Text] [Related]
24. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
[TBL] [Abstract][Full Text] [Related]
25. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
[TBL] [Abstract][Full Text] [Related]
26. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
Lilienfeld S
CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686
[TBL] [Abstract][Full Text] [Related]
27. Galantamine for Alzheimer's disease and mild cognitive impairment.
Cusi C; Cantisani TA; Celani MG; Incorvaia B; Righetti E; Candelise L;
Neuroepidemiology; 2007; 28(2):116-7. PubMed ID: 17409773
[No Abstract] [Full Text] [Related]
28. Effects of galantamine in patients with mild Alzheimer's disease.
Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
[TBL] [Abstract][Full Text] [Related]
29. The dramatic effects of Galantamine in a patient with early-onset Alzheimer's disease.
Dev H; Agius M; Zaman R
Psychiatr Danub; 2010 Jun; 22(2):367-9. PubMed ID: 20562785
[TBL] [Abstract][Full Text] [Related]
30. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study.
Kavanagh S; Van Baelen B; Schäuble B
J Alzheimers Dis; 2011; 27(3):521-30. PubMed ID: 21891871
[TBL] [Abstract][Full Text] [Related]
31. Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.
Thavichachart N; Phanthumchinda K; Chankrachang S; Praditsuwan R; Nidhinandana S; Senanarong V; Poungvarin N
Int J Clin Pract; 2006 May; 60(5):533-40. PubMed ID: 16700849
[TBL] [Abstract][Full Text] [Related]
32. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
Harry RD; Zakzanis KK
Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322
[TBL] [Abstract][Full Text] [Related]
33. A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease.
Patterson CE; Passmore AP; Crawford VL
Int J Clin Pract; 2004 Feb; 58(2):144-8. PubMed ID: 15055862
[TBL] [Abstract][Full Text] [Related]
34. Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease.
Formiga F; Fort I; Robles MJ; Rodriguez D; Regalado P
Dement Geriatr Cogn Disord; 2010; 29(3):198-203. PubMed ID: 20332637
[TBL] [Abstract][Full Text] [Related]
35. The sensitivity to change over time of the Bristol Activities of Daily Living Scale in Alzheimer's disease.
Byrne LM; Wilson PM; Bucks RS; Hughes AO; Wilcock GK
Int J Geriatr Psychiatry; 2000 Jul; 15(7):656-61. PubMed ID: 10918348
[TBL] [Abstract][Full Text] [Related]
36. The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease.
Farlow MR
Lancet Neurol; 2009 Jan; 8(1):22-3. PubMed ID: 19042160
[No Abstract] [Full Text] [Related]
37. The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease.
Dengiz AN; Kershaw P
CNS Spectr; 2004 May; 9(5):377-92. PubMed ID: 15115951
[TBL] [Abstract][Full Text] [Related]
38. Long-term progression of Alzheimer's disease in patients under antidementia drugs.
Gillette-Guyonnet S; Andrieu S; Nourhashemi F; Gardette V; Coley N; Cantet C; Gauthier S; Ousset PJ; Vellas B;
Alzheimers Dement; 2011 Nov; 7(6):579-92. PubMed ID: 22055975
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
40. Two galantamine titration regimens in patients switched from donepezil.
Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
